Experiences with
Alectinib18 public posts
FDA approval Alecensa (alectinib) following surgery for people with early stage ALK positive NSCLC
Participants with stage 1B (IB) to 3A (IIIA), ALK-positive NSCLC received 600 mg of Alecensa (alectinib) twice daily after surgery to remove the cancer.
Want to take advantage of all our features? Just log in!
or
Drug Submission time again. We are looking to speak to anyone who has experience of Loratinib (Lorviqua)
The indication this new medicine will be assessed under is: "As monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after: Alectinib or ceritinib as the first ALK tyrosine
Alectinib (Alecensa)
Medicine consortium time again. Looking for any patient and carer experience of Alectininb (Alecensa). please get in contact if you have had any experience with the drug. We don't need personal details, we just need quotes to help with the application. you can call us on 03333237200 (option 2) or you